Show simple item record

dc.contributor.authorMcLean, AK
dc.contributor.authorStewart, C
dc.contributor.authorKerridge, I
dc.date.accessioned2014-11-19T00:44:32Z
dc.date.available2014-11-19T00:44:32Z
dc.date.issued2014
dc.identifier.citationMcLean AK, Stewart C, Kerridge I, The emergence and popularisation of autologous somatic cellular therapies in Australia: Therapeutic innovation or regulatory failure? 2014. Journal of Law and Medicine, 22(1):65-89, published 22 Sept14en_AU
dc.identifier.urihttp://hdl.handle.net/2123/12282
dc.description.abstractPrivate stem cell clinics throughout Australia are providing autologous stem cell therapies for a range of chronic and debilitating illnesses despite the lack of published literature to support the clinical application of these therapies.The Therapeutic Goods Administration has excluded autologous stem cell therapies from its regulatory domain leaving such therapies to be regulated by the same mechanisms that regulate research, such as the National Health and Medical Research Council Research Ethics Guidelines, and clinical practice, such as the Australian Health Practitioner Regulation Agency. However, the provision of these stem cell therapies does not follow the established pathways for legitimate medical advance – therapeutic innovation or research. The current regulatory framework is failing to achieve its aims of protecting vulnerable patients and ensuring the proper conduct of medical practitioners in the private stem cell industry.en_AU
dc.language.isoenen_AU
dc.publisherThomson Reutersen_AU
dc.titleThe emergence and popularisation of autologous somatic cellular therapies in Australia: Therapeutic innovation or regulatory failure?en_AU
dc.typeArticleen_AU
dc.type.pubtypePublisher versionen_AU


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record